United Therapeutics (UTHR) Short term Debt (2017 - 2025)
Historic Short term Debt for United Therapeutics (UTHR) over the last 6 years, with Q1 2025 value amounting to $200.0 million.
- United Therapeutics' Short term Debt fell 5000.0% to $200.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $200.0 million, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $300.0 million for FY2024, which is 2500.0% down from last year.
- United Therapeutics' Short term Debt amounted to $200.0 million in Q1 2025, which was down 5000.0% from $300.0 million recorded in Q4 2024.
- In the past 5 years, United Therapeutics' Short term Debt registered a high of $400.0 million during Q4 2023, and its lowest value of $200.0 million during Q1 2025.
- Over the past 3 years, United Therapeutics' median Short term Debt value was $400.0 million (recorded in 2023), while the average stood at $342.9 million.
- In the last 5 years, United Therapeutics' Short term Debt soared by 3333.33% in 2024 and then tumbled by 5000.0% in 2025.
- United Therapeutics' Short term Debt (Quarter) stood at $400.0 million in 2023, then decreased by 25.0% to $300.0 million in 2024, then plummeted by 33.33% to $200.0 million in 2025.
- Its Short term Debt was $200.0 million in Q1 2025, compared to $300.0 million in Q4 2024 and $400.0 million in Q3 2024.